A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep

K-REx Repository

Show simple item record

dc.contributor.author Faburay, Bonto
dc.contributor.author Lebedev, Maxim
dc.contributor.author McVey, D. Scott
dc.contributor.author Wilson, William C.
dc.contributor.author Morozov, Igor
dc.contributor.author Young, Alan
dc.contributor.author Richt, Juergen A.
dc.date.accessioned 2015-04-06T20:39:44Z
dc.date.available 2015-04-06T20:39:44Z
dc.date.issued 2015-04-06
dc.identifier.uri http://hdl.handle.net/2097/18905
dc.description.abstract Rift Valley fever virus (RVFV), a member of the Bunyaviridae family, is a mosquito-borne zoonotic pathogen that causes serious morbidity and mortality in livestock and humans. The recent spread of the virus beyond its traditional endemic boundaries in Africa to the Arabian Peninsula coupled with the presence of susceptible vectors in non-endemic countries has created increased interest in RVF vaccines. Subunit vaccines composed of specific virus proteins expressed in eukaryotic or prokaryotic expression systems are shown to elicit neutralizing antibodies in susceptible hosts. RVFV structural proteins, N-terminus glycoprotein (Gn) and C-terminus glycoprotein (Gc), were expressed using a recombinant baculovirus expression system. The recombinant proteins were reconstituted as GnGc subunit vaccine formulation and evaluated for immunogenicity in a target species, sheep. Six sheep were each immunized with a primary dose of 50 μg of each vaccine immunogen adjuvanted with montanide ISA25, and at day 21 post-vaccination, each animal received a second dose of the same vaccine. The vaccine induced strong antibody response in all animals as determined by indirect enzyme-linked immunosorbent assay (ELISA). Plaque reduction neutralization test (PRNT80) showed the primary dose of the vaccine was sufficient to elicit potentially protective virus neutralizing antibody titers ranging from 40 to 160, and the second vaccine dose boosted the titer to more than 1,280. Further, all animals tested positive for neutralizing antibodies at day 328 pv. ELISA analysis using the recombinant nucleocapsid protein as a negative marker antigen indicated that the vaccine candidate is DIVA (differentiating infected from vaccinated animals) compatible, and represents a promising vaccine platform for RVFV infection in susceptible species. en_US
dc.language.iso en_US en_US
dc.relation.uri http://doi.org/10.1089/vbz.2014.1650 en_US
dc.rights Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/vbz.2014.1650 en_US
dc.subject Rift Valley fever virus en_US
dc.subject Glycoproteins en_US
dc.subject Subunit vaccine en_US
dc.subject Neutralizing antibodies en_US
dc.subject Sheep en_US
dc.title A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep en_US
dc.type Article (author version) en_US
dc.date.published 2014 en_US
dc.citation.doi 10.1089/vbz.2014.1650 en_US
dc.citation.epage 756 en_US
dc.citation.issue 10 en_US
dc.citation.jtitle Vector-Borne and Zoonotic Diseases en_US
dc.citation.spage 746 en_US
dc.citation.volume 14 en_US
dc.contributor.authoreid bfaburay en_US
dc.contributor.authoreid dsmcvey en_US
dc.contributor.authoreid wcwilson en_US
dc.contributor.authoreid imorozov en_US
dc.contributor.authoreid jricht en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search K-REx

Advanced Search


My Account


Center for the

Advancement of Digital